Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 01 Mar 2023
Benign prostatic hyperplasia (BPH) is a condition in which the prostate gland enlarges, causing problems or obstruction in urination...
Read Full NewsA nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.
The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.
Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.
REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis
1.
WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research
2.
Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.
3.
PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.
4.
A healthier lifestyle after bowel screening shown to prevent bowel cancer
5.
It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.
1.
Revolutionizing Oncology: Pharmacometric Models in Personalized Cancer Drug Development
2.
Phosphate Vs. Phosphorus: What Is The Difference?
3.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
4.
Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer
5.
Oncology Drug Trends 2025: FDA Approvals, Immuno-Oncology, and Clinical Trial Insights
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
4.
Navigating the Complexities of Ph Negative ALL - Part VI
5.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge